Xencor Inc (XNCR): Revenue
$125.58M
Year ended 2025-12-31
$104.97M
Trailing 12 months to 2026-06-30
-8.6%
3-year compound annual growth
+0.5%
5-year compound annual growth
| Period ended | Revenue | Change YoY | Source filing |
|---|---|---|---|
| 2025-12-31 | $125.58M | +13.7% | 2026-02-25, From 2025-01-01 |
| 2024-12-31 | $110.49M | -36.7% | 2026-02-25, From 2024-01-01 |
| 2023-12-31 | $174.62M | +6.1% | 2026-02-25, From 2023-01-01 |
| 2022-12-31 | $164.58M | -40.2% | 2025-02-27, From 2022-01-01 |
| 2021-12-31 | $275.11M | +124.2% | 2025-02-24, From 2021-01-01 |
| 2020-12-31 | $122.69M | -21.7% | 2023-02-27, From 2020-01-01 |
| 2019-12-31 | $156.70M | +285.9% | 2022-02-24, From 2019-01-01 |
| 2018-12-31 | $40.60M | -12.0% | 2021-02-24, From 2018-01-01 |
| 2017-12-31 | $46.15M | -57.7% | 2020-02-25, From 2017-01-01 |
| 2016-12-31 | $109.02M | n/a | 2019-02-26, From 2016-01-01 |
Revenue at similar companies
| Company | Year ended | Revenue | Change YoY |
|---|---|---|---|
| Xencor Inc (XNCR) | 2025-12-31 | $125.58M | +13.7% |
| Lifecore Biomedical, Inc. (LFCR) | 2025-05-25 | $128.87M | +0.5% |
| Gyre Therapeutics, Inc. (GYRE) | 2025-12-31 | $116.59M | +10.2% |
| UroGen Pharma Ltd. (URGN) | 2025-12-31 | $109.79M | +21.4% |
| Karyopharm Therapeutics Inc. (KPTI) | 2025-12-31 | $146.07M | +0.6% |
| Zevra Therapeutics, Inc. (ZVRA) | 2025-12-31 | $106.47M | +350.9% |
| Zymeworks Inc. (ZYME) | 2025-12-31 | $105.97M | +38.9% |
| Elite Pharmaceuticals Inc (ELTP) | 2026-03-31 | $148.87M | +77.1% |
| Macrogenics Inc (MGNX) | 2025-12-31 | $149.50M | -0.3% |
Compare XNCR, LFCR, GYRE, URGN side by side · Screen every company in Pharmaceutical Preparations ↗